搜尋結果
Dosage/Direction for Use. Taken for 28 consecutive days, followed by a 14-day rest. Initial dose can be decreased according to patient's condition. Lower limit: 40 mg. Adult BSA ≥1.5 m2 Initially 60 mg bd, 1.25 to <1.5 m2 Initially 50 mg bd, <1.25 m2 Initially 40 mg bd. Click to view TS-One detailed prescribing information.
Dosage/Direction for Use. Microgynon 30 1 tab daily at about the same time every day, for 21 days starting on the 1st day of menstrual cycle, followed by 7 tab-free days. Microgynon 30 ED 1 tab daily at about the same time every day, starting on the 1st day of menstrual cycle. Take the 1st tab from the red area on the blister pack corresponding ...
IM Primary vaccination schedule of 2 doses (0.5 mL each): Initial dose followed by 2nd dose 2 mth later. If flexibility in the vaccination schedule is necessary, 2nd dose can be administered between 2 & 6 mth after the 1st dose. Immunodeficient or immunosuppressed individual 2nd dose can be given 1-2 mth after the initial dose.
Initial dose should be administered as a 90-min IV infusion. If prior infusion was well tolerated, subsequent doses may be administered as 30-min infusions. Breast cancer 5.4 mg/kg IV infusion once every 3 wk (21-day cycle) until disease progression or unacceptable toxicity. Gastric cancer 6.4 mg/kg IV infusion once every 3 wk (21-day cycle ...
Entecavir. Indications/Uses. Treatment of chronic HBV infection in adults w/ evidence of active viral replication & either evidence of persistent elevations in serum ALT or AST or histologically active disease. Click to view Hepavance detailed prescribing information. Dosage/Direction for Use.
Dosage/Direction for Use. Individualized dosing. 30-60 mg/kg IV over 30-120 min daily for 5 consecutive days or 125-200 mg/kg IV over 24 hr per cycle. Therapy cycles may be repeated every 3-4 wk. Click to view Holoxan detailed prescribing information.
Tagrisso FC tab 40 mg. Packing/Price. 30's. Form. Tagrisso FC tab 80 mg. Packing/Price. 30's. Tagrisso (Osimertinib mesylate): Adjuvant treatment after complete tumour resection in adults w/ stage IB-IIIA NSCLC whose tumours have epidermal growth fac.
